Antiverse

At Antiverse, we are engineering the future of drug discovery. We have developed an Artificial Intelligence (AI)-powered de novo drug discovery platform, which uses hyper-expressing cell lines and machine learning to design antibodies against various targets. Our technology facilitates the development of antibodies capable of binding challenging drug targets, including G-protein coupled receptors (GPCRs) and ion channels, over a 6-month timeline. We are passionate about what we do and the impact our discoveries have on patients across the globe. Based in Cardiff, our expert team spans structural biology, machine learning and medicine - and together, we are catalysing the next shift in AI-augmented drug discovery.